603520 Zhejiang Starry Pharmaceutical
- 12.29
- -0.11-0.89%
Zhejiang Starry Pharmaceutical News
Stari (603520): Iodine prices fall, profits release, and dosage of formulations drive growth
Core view The company's revenue performance in 2023 and 24Q1 was steady, and the profit side reversed losses. The formulation business performed well, and domestic formulations grew rapidly. Profitability is steady, sales expenses have increased along with formulation promotion, and operating cash flow continues to be excellent
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) 10.0% Gain Last Week Benefited Both Retail Investors Who Own 48% as Well as Insiders
Key Insights Zhejiang Starry PharmaceuticalLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 15 shareholders
Stari (603520): The inflection point in performance is now in the short term, look at costs in the medium to long term, and look at API+ formulation dosage
Matters: The company announced its 2023 annual report, achieving revenue of 2.196 billion yuan (+3.04%), net profit of 44 million yuan (+158.32%), and net profit of 36 million yuan (+136.47%) after deducting net income to mother
Stelli (603520): Marginal improvement in upstream raw material prices
The marginal decline in iodine prices for upstream raw materials in '23 drove profit side to reverse losses. It is expected to continue to improve the company's 4/29 release performance in '24, achieve revenue of 2.196 billion yuan (+3.0% yoy) in '23, and net profit of zero to mother.
Stari (603520.SH): Net profit of 12.282,500 yuan in the first quarter increased 28.37% year-on-year
On April 29, Ge Longhui (603520.SH) released its report for the first quarter of 2024, achieving operating income of 642 million yuan, an increase of 13.50%; net profit attributable to shareholders of listed companies of 12.282,500 yuan, an increase of 28.37% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 9.831 million yuan, an increase of 31.85% year on year; basic earnings per share were 0.04 yuan.
Improved Revenues Required Before Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Stock's 28% Jump Looks Justified
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month, although it is still struggling to make up recent
These 4 Measures Indicate That Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Is Using Debt In A Risky Way
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Express News | Sitaili: Application for registration to issue shares to specific targets approved by the Securities Regulatory Commission
Stary (603520.SH)'s application for fixed addition was approved by the China Securities Regulatory Commission
Stelli (603520.SH) announced that the company received it from the China Securities Regulatory Commission on March 13, 2024...
Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Adds CN¥435m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 77%
It's nice to see the Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) share price up 13% in a week. But only the myopic could ignore the astounding decline over three years. In that time the
Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) shares are down a considerable 26% in the last month, which continues a horrid run for the company. For
Stari (603520.SH): Net profit pre-profit of 40 million yuan to 50 million yuan in 2023
Gelonghui, January 30丨Stelli (603520.SH) announced the 2023 annual results forecast. According to preliminary estimates by the finance department, it is expected to achieve net profit of 40 million yuan to 50 million yuan for the full year of 2023. Compared with the same period last year, it will turn a loss into a profit. It is expected to achieve net profit of 30 million yuan to 40 million yuan after deducting non-recurring profit and loss attributable to the owners of the parent company in 2023.
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Stock Price Dropped 8.9% Last Week; Retail Investors Would Not Be Happy
Key Insights The considerable ownership by retail investors in Zhejiang Starry PharmaceuticalLtd indicates that they collectively have a greater say in management and business strategy 51% of the bu
[BT Financial Report Instantaneous Analysis] Steali's 2023 Three-Quarter Report: Sales Expansion Drives Profit Growth, and Cash Flow Has Improved Significantly
Zhejiang Sitaili Pharmaceutical Co., Ltd. (stock code: 603520), as an important force in the domestic pharmaceutical industry, focuses on R&D, production and sales of pharmaceutical specialty APIs and formulations. The company has nearly 20 years of industry experience. The product line covers nonionic iodine contrast agent series drugs and levofloxacin series of APIs and intermediates. With rich customer resources and a mature market-oriented business model, Sitaili has taken a place among high-tech pharmaceutical enterprises. From the perspective of assets and liabilities, Stelli's total assets as of the end of the third quarter of 2023 reached 5.7 billion yuan, compared to the end of the previous year
Si Taili (603520) Commentary on the 2023 Quarterly Report: The revenue side maintains relatively rapid growth and waits for iodine prices to fall
Matters: On October 31, 2023, the company announced its three-quarter report. 2023Q1-Q3 achieved operating income of 1,631 billion yuan (+18.4%) and net profit of 39 million yuan (+101.17%)
Si Taili (603520): Raw material costs affect performance, wait for the iodine price inflection point
Event: The company released its 2023 three-quarter report. The first three quarters achieved operating income of 1,631 billion yuan, an increase of 18.43% over the previous year; net profit of 39.32 million yuan, an increase of 101.17% over the previous year; and deducted non-net profit of 272
Si Taili (603520.SH): Net profit for the first three quarters was 39.317,500 yuan, up 101.17% year on year
On October 30, Gelonghui (603520.SH) announced its third quarter report. Operating income was 1.63 billion yuan, up 18.43% year on year, net profit was 39.317,500 yuan, up 101.17% year on year, net profit was 39.317,500 yuan, minus non-net profit of 272.16 million yuan, up 520.59% year on year, and basic earnings per share of 0.11 yuan.
Si Taili (603520): The contrast agent industry has room for long-term development, and is expected to further expand production capacity in the future after approval of the fixed increase review
The company released the 2023 three-quarter report: the first three quarters achieved revenue of 1,631 billion yuan, an increase of 18.43% over the previous year; net profit of 39.32 million yuan, an increase of 101.17% over the previous year; and deducted non-net profit of 27.22 million yuan
Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Market Cap Dropped CN¥393m Last Week; Retail Investors Bore the Brunt
Key Insights Zhejiang Starry PharmaceuticalLtd's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 11 shareholders
Si Taili (603520.SH): The application for stock increase was reviewed and approved by the Shanghai Stock Exchange
Si Taili (603520.SH) announced that the company received it on the Shanghai Stock Exchange on October 19, 2023...
Analysis
Price Target
No Data
